Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

By Chang Myung   Kim Kyoung   Jun Hyun   Kim Hyo   Yi Seong   Uhm Ji   Park Min   Lim Do   Ji Sang   Hwang In   Lee Jeeyun   Park Yeon   Ahn Jin   Ahn Myung-ju   Park Keunchil  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 917-924

Springer Publishing Company

Access to resources Recommend Favorite

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

By  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1133-1133

Oxford University Press

Access to resources Recommend Favorite